Ensure biometric attendance is marked accurately as per NMC norms: KGMU directs Faculty, residents, warns against failure

Lucknow- King George’s Medical University (KGMU) has asked all the faculty and resident doctors in the institute to ensure that their attendance is marked accurately as mandated by the National Medical Commission (NMC).

This comes after the recently held online meeting between KGMU and NMC. KGMU Vice Chancellor Prof. Sonia Nithyananda has issued a circular on this, stating that ”This circular serves as a reminder of the recent online meeting held with the National Medical Commission (NMC), New Delhi, during which it was emphasized that all faculty members and residents of our esteemed University are required to mark their attendance on Aadhar Enabled Biometric Machines”.

Warning against failure, the notice further stated “The NMC has mandated this biometric attendance system for all faculty members and residents. Failure to comply with this mandate may result in adverse actions against the University, including heavy fines, reduction of MBBS/PG/Super Specialty seats and the potential surrender of courses”.

Therefore, while strictly instructing all the faculty members and residents the notice added “It is imperative that all faculty members and residents adhere strictly to this directive and ensure their attendance is marked accurately on the Aadhar Enabled Biometric Machines”.

Last year, NMC reiterated the importance of Aadhaar-enabled biometric attendance system (AEBAS) for faculty members before inspection to address the menace of ghost faculty in government and private medical colleges.

Medical dialogues had earlier reported about NMC issuing show-cause notices to 100 medical colleges across the country as the faculties in those institutes failed to meet the 75% attendance criteria. All these medical colleges have been given 15 days to reply to the notice, failing which they will face punitive action.

Faculty shortage has remained an obstacle for several medical colleges across the country. To meet the faculty requirements, several medical colleges take help from guest lecturers, even though it is not permitted under the NMC rules.

Meanwhile, the NMC rules specify that undergraduate and postgraduate medical colleges imparting medical education must ensure that their faculties have 75% attendance of the total working days.

Last year, the Undergraduate Medical Education Board (UGMEB) of NMC notified the “Guidelines for Under Graduate Courses under Establishment of New Medical Institutions, Starting of New Medical Courses, Increase of Seats for Existing Courses & Assessment and Rating Regulations, 2023”, or the UG-MSR-2023 on August 16, 2023 in its official Gazette.

Para 3.1 (i) & (ii) of UG-MSR 2023 specifies that all medical colleges shall install an Aadhaar-Enabled Biometric Attendance System (AEBAS) to be linked to Command and Control center of NMC and the daily AEBAS of the required staff (faculty, residents and supporting staff), preferably along with face linked recognition, shall be made available to NMC as well as on the Medical College Website in the form of daily attendance dashboard.

Further, these guidelines also specified that it shall be mandatory for medical colleges to have at least 75% of the total working days (excluding vacations) for all faculty and resident doctors.

To view the notice, click the link below

Powered by WPeMatico

GSK Pharma declares financial results for quarter ended March 31, 2024

Mumbai: GlaxoSmithKline (GSK) Pharmaceuticals Limited has declared
financial results for the quarter ended March 31, 2024. Revenue for the quarter came in at Rs. 911
crores recorded a growth of 16%.

Profit before exceptional items and tax for the quarter at Rs.266
crores recorded a growth of 51% with EBITDA margins at 28%.
The full year reported revenue was at Rs 3407 crores, a growth of 6%, demonstrating positive
growth driven by a strong volume recovery thereby offsetting NLEM (National List of Essential
Medicines) impact.

Profit before exceptional items and tax for the year at Rs. 953 crores recorded
a growth of 14% with EBITDA at 26.4% up by 150 bps.

Commenting on the results for Q4 and FY 2023-24, Bhushan Akshikar, Managing Director,
GlaxoSmithKline Pharmaceuticals Limited, said, “For Q4, we delivered a strong double-digit
growth and a robust performance across our General Medicines, Specialty and Vaccines portfolio.
Our General Medicines portfolio recorded strong double-digit growth of 12% for the quarter, driven
by key focus brands Augmentin, Ceftum and Calpol. Despite the NLEM impact in previous
quarters, all promoted brands outpaced their respective categories in growth and gained market
share.
Specialty portfolio led by Nucala and Trelegy has accelerated the momentum with highest patient
recruitment in Q4.
For the vaccines business, over the last two quarters, we have seen a steady upswing in both adult
and paediatric segments. This business delivered a Q4 growth of 35%. We continue to build on
the momentum generated with the launch of Shingrix (Zoster Vaccine Recombinant, Adjuvanted)
as we drive expansion of the Adult Immunisation category in India with innovative go-to-market
(GTM) strategies.We also remain committed to accelerating digital transformation to drive focused reach, coverage
and seamless omni-channel experience for our customers.”

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a global healthcare company.

Read also: GSK application for expanded indication of Jemperli plus chemotherapy accepted by USFDA for priority review

Powered by WPeMatico

One Health approach in bolstering public health efforts in Kerala: Health Minister Veena George

Thiruvananthapuram: The Kerala Government stresses importance of ‘One Health’ Approach for Public Health Enhancement, said State Health Minister Veena George at the conclusion of the Trivandrum Management Association’s annual event, TRIMA,

Minister Veena George underscored the significance of a collaborative ‘One Health’ approach in bolstering public health efforts in Kerala.

According to a ANI report,”Since the outbreaks of Nipah and COVID-19, the concept of One Health has gained attention. The state government has established a One Health Institute and centres in Thiruvananthapuram and Kozhikode. We have trained 2,50,000 volunteers to report and connect with government and local communities across Kerala,” the minister said.

Also Read:Kerala placed on high alert as West Nile Virus cases identified in Kozhikode, Thrissur, Malappuram

Understanding the importance of One Health, the state government has revised its health policy, and a Public Health Act was passed by the legislative assembly last year.

“We have established teams at the local level, including officers from the health department, water authority, pollution control board, and animal husbandry, with the panchayat president as the chairman. These committees will help quickly identify infection outbreaks and respond locally, ensuring close monitoring of the situation,” she added.

She emphasised that only through the collaborative and collective efforts of various departments can the state effectively combat the threat of infectious diseases. She also expressed hope that ongoing studies by ICMR on the spillover process in Nipah would yield conclusions this year.

Highlighting major health challenges, she pointed out that dengue and chikungunya are significant concerns, along with the recent avian flu cases in Alappuzha and Kottayam. Although the avian flu has not affected humans in Kerala, globally, 800 people have been impacted. The flu could be disastrous if it transmits to humans, and the state health department is closely monitoring the situation, news agency ANI reported.

Notable speakers at the event included TP Sreenivasan, former Ambassador and Chairman of TRIMA, Air Marshal (Retd) IP Vipin, Co-chair of TRIMA, Dr. Ritu Singh Chauhan, National Professional Officer, IHR, WHO, C Padmakumar, President of TMA, and Wing Commander Ragashree D Nair, Secretary of TMA.

According to the World Health Organization, ‘One Health’ is an integrated, unifying approach to balance and optimize the health of people, animals and the environment. It is particularly important to prevent, predict, detect, and respond to global health threats such as the COVID-19 pandemic.

Powered by WPeMatico

12 Seats Vacant in AIIMS Mangalagiri for MSc Nursing Admissions August 2024 Session

Mangalagiri- The examination section of All India Institute of Medical Sciences (AIIMS) has released the seat matrix for the MSc Nursing courses of AIIMS Mangalagiri for the August 2024 session.

As per the seat matrix, there are a total of 6 MSc Nursing courses and a total of 12 vacant seats in 6 categories i.e. UR, OBC, SC, ST, EWS and PWBD.

The Seat Matrix has been released in pursuance of the communication received from Registrar (Academic) AIIMS New Delhi”, an official notice on this stated.

SEAT MATRIX

S.NO

COURSE

TOTAL

UR

OBC

SC

ST

EWS

PwBD

1

Medical-Surgical Nursing.

2

2

0

0

0

0

01

(UR)

2

Obstetric and Gynaecological Nursing.

2

1

1

0

0

0

3

Oncology Nursing.

2

1

1

0

0

0

4

Paediatric Nursing.

2

2

0

0

0

0

5

Psychiatric Nursing.

4

1

1

1

0

1

TOTAL

12

7

3

1

0

1

Candidates are requested to keep visiting the official website of AIIMS as all the important notifications, corrigendum, addendum and updates etc will be uploaded on the website only, the notice added.

To view the seat matrix, click the link below

The seat matrix has been released regarding admission to BSc (H) Nursing/BSc Nursing (Post-Basic)/BSc (Paramedical Course) and MSc Nursing/MSc Course/M Biotechnology for August 2024 session in AIIMS New Delhi and other AIIMS.

On this, AIIMS has recently released the revised exam dates of the entrance examinations for admission to the said courses.

REVISED DATES

The entrance exam for the B.Sc (Hons) Nursing, B.Sc (Paramedical), B.Sc (Post-Basic), MSc Nursing, M.Sc courses and M. Biotechnology is revised as per the following schedule-

S.NO

PARTICULARS

PREVIOUS DATES

REVISED DATES

1

Online Entrance Examination (CBT mode) for B.Sc.(Hons.) Nursing courses August 2024 session.

08.06.2024 (Saturday).

08.06.2024 (Saturday) & 09.06.2024 (Sunday).

2

Online Entrance Examination (CBT mode) for B.Sc. Paramedical & B.Sc (Post-Basic) Courses for the August 2024 session.

22.06.2024 (Saturday).

06.07.2024 (Saturday).

3

Online Entrance Examination (CBT mode) for M.Sc. courses/M.Sc Nursing/M. Biotechnology courses for the August 2024 session.

15.06.2024 (Saturday).

No change.

Powered by WPeMatico

Renew Blood Bank License or pay Rs 6 lakh Penalty for Non-Compliance: NMC warns Medinirai Medical College Hospital

Daltonganj: The Medinirai Medical College Hospital (MMCH), Daltonganj has now come under the National Medical Commission’s (NMC) scanner as the licence of its blood bank expired on September 30, 2020. Directing the institute to renew the licence by July 10, the Apex Medical Education Regulatory Body has warned to slap a Rs 6 Lakh penalty on the institute for non-compliance.

The Central Drugs Standard Control Organisation (CDSCO), operative under the Union Ministry of Health and Family Welfare, issues this licence through the State unit.

Also Read: Medical Colleges Under Tight Scrutiny of National Medical Commission

As per the latest media report by the Times of India, during its meeting with the MMCH Principal Dr. Kamender Prasad on May 10, NMC stressed the importance of updating the blood bank’s license. Responding to this, Dr. Prasad informed the Commission that the college was pursuing the matter with the drug inspector of Palamu Chandan Kachchap.

Meanwhile, Chandan said the drug inspector for the east zone in Kolkata, Ashutosh Kumar inspected the blood bank on April 3. He added that the delay in renewing the licence for the blood bank since 2020 was due to certain deficiencies, such as the absence of an Eliza machine and a non-functional temperature graph device in the blood bank’s fridge.

Commenting on the matter, a senior official at the blood bank, Anwar Alam informed that an Eliza machine was purchased and two fridges with advanced temperature graph devices have been installed.

NMC scrutiny and action

Medical Dialogues had earlier reported that the NMC had been in talks with the medical colleges across the country on a daily basis to ensure that the medical colleges have been complying with the requirements regarding faculty numbers, biometric attendance, clinical materials and other rules. The process is ongoing and NMC has already reached out to the administrators of around half of the medical colleges.

Earlier, medical colleges were facing physical inspections, where a team of assessors would go and visit medical colleges and assess those facilities. This process was widely criticized and accused of being full of bribery and corruption. It was alleged that the assessor would take bribes and approve medical colleges. However, under the new system, the Apex Medical Regulator is slowly moving online in terms of inspection of medical colleges as well as overseeing the fulfilment of requirements. Although online, with features, like AEBAS and biometric attendance system, it is being difficult for medical colleges to engage ghost faculties.

Also Read: First time: NMC slaps fine on 3 TN medical colleges for Faculty, Clinical Material Deficiencies

Earlier this month, for the first time, taking note of deficiencies in faculty and clinical material, NMC imposed fines on medical colleges for violating the Maintenance of Standards of Medical Education Regulations, 2023 (MSMER) rules. The Commission slapped a fine of up to Rs 3 lakh on government medical colleges in Tamil Nadu, including the colleges in Dharmapuri, Ramanathapuram, and Nagapattinam. Apart from these colleges, the Commission also issued show-cause notices to many other colleges for deficiencies in Aadhaar-based biometric attendance.

Recently, taking cognisance of a critical faculty shortage and lack of essential resources, the Commission took strict action against the government medical colleges in Chhattiagarh. NMC slapped a penalty of Rs 1 crore on Kanker Medical College, Rs 4 lakh fine on Durg Medical College, and Rs 3 lakh fine each in the medical colleges located at Bilaspur, Ambikapur, Mahasamund, and Jagdalpur. Along with this, Mahasamund, Kanker, and Raigarh medical colleges have also been served with show-cause notices over the shortage of faculty.

Powered by WPeMatico

Use MvPI platform for reporting any adverse events linked to medical devices: CDSCO

New Delhi: With an aim to enhance the procedure for identifying the risk associated with Medical Devices, through a recent notification, the Ministry of Health and Family Welfare, Directorate General of Health Services, Central Drugs Standard Control Organisation, has suggested that all medical device license holder should use the Materiovigilance Programme of India (MvPI) platform for reporting of any adverse events/serious adverse events associated with the devices.

Furthermore, the notice added that all medical device license holders are requested to take appropriate action for timely reporting of adverse events related to medical devices to MvPI.

“Guidance documents developed for effective utilization of MvPI are available on IPC website (https://www.ipc.gov.in.). If any training is required to enhance understanding and proficiency in adverse event reporting processes, you may please contact mvpi­ ipc@gov.in.” notice added.

Currently, all Medical Devices including In-vitro diagnostic medical devices have come under the regulation under the Drugs and Cosmetics Act, 1940, and Medical Devices Rules, 2017. A License/ approval is required for the import/manufacture of marketing of the devices in the country. The licenses are issued under the said rules with certain conditions, to ensure the quality, safety, and performance of Medical Devices available in the market, as well as to ensure compliance with the Quality Management System.

The circular also highlighted that all medical device license holders establish robust systems and processes for the timely identification, documentation, and reporting of adverse events associated with medical devices.

In continuation with the above, it noted, “The Post-market surveillance (PMS) of medical devices one of the important aspects to ensure safety and performance of the medical devices.PMS supports to identify and address any potential risk or adverse event associated with the medical device. Timely reporting of the Adverse events allows for the identification of unidentifiable risks, analysing frequency of already identified risks and enabling the manufacturers and regulatory authorities to take appropriate measures to mitigate these risks and safeguard public health.”

The Materiovigilance Programme of India (MvPI) was launched by the Ministry of Health and Family Welfare, Government of India with the objective of improving Indian patient safety by monitoring, recording, and analyzing the root cause of adverse events or risks associated with the use of medical devices including in­ vitro diagnostics by healthcare professionals or patients/users and suggesting regulatory bodies for appropriate action with the sole intention of improving patient safety.

Indian Pharmacopeia Commission (IPC) has been entrusted with National Coordination Centre responsibilities related to the Materiovigilance Programme of India (MvPI).

Apart from healthcare professionals/general public/users/patients, the Medical devices industry is one of the major stakeholders of MvPI, their participation needs to be encouraged to make a significant impact on the outcome.

In line with the above, the notice stated,

“As the MvPI is an important program for reporting adverse events, coordinated analysis, etc related to Medical Devices including In-vitro diagnostic devices, therefore it is suggested that all the license holders should also use the MvPI platform for reporting any Adverse events/Serious adverse events associated with the devices to enhance the procedure for identifying risk associated with Medical Devices.”

Moreover, the notice suggested to all medical device license holders,

“In view of the above, you are requested to take appropriate action for timely reporting of adverse events related to medical devices to MvPI. Guidance documents developed for the effective utilization of MvPI is available on the IPC website (https://www.ipc.gov.in.). If any training is required to enhance understanding and proficiency in adverse event reporting processes, you may please contact mvpi­ ipc@gov.in.”

To view the official notice, click the link below:

Also Read:Alkem Laboratories Gets CDSCO Panel Nod To Manufacture Market Relugolix Tablets 120mg

Powered by WPeMatico

Doctor saves life of child who collapsed after electric shock

In a heartwarming display of medical heroism, an Andhra Pradesh doctor’s quick actions saved the life of a 6-year-old boy who was electrocuted in Ayyappa Nagar, Vijayawada. The boy’s frantic parents were carrying him along the road when he suddenly went into cardiac arrest.

Dr. Ravalika, who happened to be passing by, noticed the distress and immediately sprang into action. Demonstrating remarkable presence of mind, she performed CPR (Cardiopulmonary Resuscitation) on the boy right there on the road. A video captured the tense moments as Dr. Ravalika continuously thumped the boy’s chest while he lay lifeless, with passersby clearing the road to allow her space to work.

After several attempts, Dr. Ravalika successfully revived the child. After five tense minutes, the boy began breathing again. He was then rushed to a hospital for further treatment and has since made a full recovery.

Powered by WPeMatico

NEET 2024 paper leak matter reaches SC, plea seeking stay on results declaration junked

The paper leak scandal involving the National Eligibility-cum-Entrance Test Undergraduate (NEET-UG) 2024 Exam has now reached the Supreme Court. While the bench refused to grant a stay on the exam results, it has agreed to consider the matter and issue notice on the Public Interest Litigation seeking re-conduction of the NEET UG exams in light of the alleged malpractices and paper leak scam.

The bench comprising Chief Justice of India DY Chandrachud and Justices JB Pardiwala and Manoj Misra has posted the matter for further hearing after the summer vacations (in July). However, the CJI observed that the results of ‘an all-India exam’ cannot be stayed at the moment, Live Law has reported.

For more information, click on the link below:

NEET 2024 Paper Leak Matter Reaches Supreme Court, Plea Seeking Stay On Results Declaration Junked


Powered by WPeMatico

DGHS requests repatriation of 20 doctors on deputation in Chandigarh for over 10 years

Chandigarh: The Director General Health Services (DGHS) of Haryana has initiated efforts to repatriate around 20 doctors who have been posted on deputation to the Chandigarh health department for over a decade. 

A significant number of doctors who have exceeded these deputation limits were mentioned in the list provided by DGHS. It includes 6 senior medical officers who have been on deputation for over 14 years and 16 medical officers for over 9 years.

In an official letter, the DGHS has asked the additional chief secretary of health, Haryana, to address this matter with the UT administration. The letter mentioned, “If higher authorities agree, the government may be requested to do the needful for repatriation of those doctors who are staying on deputation for more than five years in Chandigarh administration.”

Also read- How To Appoint HoDs In Central Govt Hospitals, Associated Medical Colleges? Health Ministry Releases New Guidelines

According to the Haryana Civil Services Rules, 2016, the standard duration for deputation from any government position is up to three years. However, this period can be extended to a maximum of five years if deemed necessary for the public interest. However, prior approval of the administrative department and finance department must be obtained well in time, TOI reports. 

Earlier, the Director General of Health Sciences (DGHS) directed all the healthcare workers of Central government hospitals not to wear jewellery below the elbow and restrict the use of mobile phones while on duty in critical areas to safeguard the well-being of both patients and healthcare personnel as reported by Medical Dialogues team. 

Jewellery below the elbow and usage of mobile phones while on duty have been prohibited to prevent the potential spread of infection and minimize infection risks.

In addition, it has been directed to create and implement a policy that limits the usage of cell phones in patient zones and high-risk areas like ICUs, HDUs, post-operative wards, and operation rooms.

Also read- Restrict Mobile Phone Use On Duty, No Jewellery Below Elbow: DGHS Advisory For Healthcare Workers

Powered by WPeMatico

CDSCO panel noted Biological E’s Post Marketing Surveillance Report of Monovalent recombinant Hepatitis-B vaccine

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has noted the post-marketing surveillance report of the Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules”.

This came after the vaccine major Biological E presented the post-marketing surveillance report of the Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post-marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules”.

Hepatitis B Vaccine (Recombinant) is composed of highly purified hepatitis B surface antigen (HBsAg) adsorbed to an aluminum adjuvant. The antigen is produced from the fermentation of a recombinant strain of yeast, Saccharomyces cerevisiae.

At the recent SEC meeting for Vaccine 30th April 2024, the expert panel reviewed the post-marketing surveillance report of Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules” presented by the drug major Biological E.

After detailed deliberation, the committee noted the results of the PMS study as presented by the firm.

Also Read: Biological E Gets CDSCO Panel Nod for Continued Safety study of 14-valent pneumococcal polysaccharide conjugate vaccine

Powered by WPeMatico